These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18065782)

  • 1. Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.
    Steinman TI
    Nephrol Dial Transplant; 2008 Feb; 23(2):431-3. PubMed ID: 18065782
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Ulusoy S; Ozkan G; Orem C; Kaynar K; Koşucu P; Kiriş A
    Ren Fail; 2010; 32(8):913-7. PubMed ID: 20722556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ACE inhibitors for diabetic patients. passed the test on the heart and kidneys].
    MMW Fortschr Med; 2002 Oct; 144(44):53. PubMed ID: 12494601
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].
    Vítovec J; Spinar J
    Vnitr Lek; 1998 Jun; 44(6):336-41. PubMed ID: 9820056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vagal cardiac activity in essential hypertension: the effects of metoprolol and ramipril.
    Vesalainen RK; Kantola IM; Airaksinen KE; Tahvanainen KU; Kaila TJ
    Am J Hypertens; 1998 Jun; 11(6 Pt 1):649-58. PubMed ID: 9657623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antihypertensive therapy with left cardiac insufficiency].
    Schröder H
    Med Monatsschr Pharm; 2005 Dec; 28(12):443-4. PubMed ID: 16389872
    [No Abstract]   [Full Text] [Related]  

  • 8. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ramipril and new therapeutic possibilities for ACE-inhibitors].
    Vespasiani Gentilucci U; Picardi A
    Clin Ter; 2000; 151(4):307-8. PubMed ID: 11107682
    [No Abstract]   [Full Text] [Related]  

  • 10. S-metoprolol: the 2008 clinical review.
    Dasbiswas A; Shinde S; Dasbiswas D
    J Indian Med Assoc; 2008 Apr; 106(4):259-62. PubMed ID: 18828349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The metabolic effects of isradipine, ramipril, Ednit and beta-adrenoblockers in patients with non-insulin-dependent diabetes mellitus and arterial hypertension].
    Morugova TV; Lazareva DN
    Eksp Klin Farmakol; 1999; 62(2):39-42. PubMed ID: 10340128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramipril: the better angiotensin-converting enzyme inhibitor?
    Gupta R
    Indian Heart J; 2008; 60(3):188-91. PubMed ID: 19240304
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal medulla and bradykinin during the development of hypertension in SHR.
    O'Sullivan JB; Bertram JF; Harrap SB
    Clin Exp Pharmacol Physiol; 1995; 22(6-7):463-5. PubMed ID: 8582104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metoprolol and ramipril on action potentials after myocardial infarction in rats.
    Wagner K; Kamkin A; Kiseleva I; Theres H; Scholz H; Günther J
    Eur J Pharmacol; 2000 Feb; 388(3):263-6. PubMed ID: 10675735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal volume in children with ADPKD: size matters.
    Chapman AB; Guay-Woodford LM
    Clin J Am Soc Nephrol; 2009 Apr; 4(4):698-9. PubMed ID: 19339418
    [No Abstract]   [Full Text] [Related]  

  • 16. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).
    Cadnapaphornchai MA; Fick-Brosnahan GM; Duley I; Johnson AM; Strain JD; DeGroff CG; Schrier RW
    Contemp Clin Trials; 2005 Apr; 26(2):211-22. PubMed ID: 15837441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making an earlier diagnosis of ADPKD: implications for the treatment of hypertension.
    Perrone R; Miskulin DC
    Nephrol News Issues; 2006 Jun; 20(7):32, 35-6. PubMed ID: 16764142
    [No Abstract]   [Full Text] [Related]  

  • 18. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
    Tkachenko O; Helal I; Shchekochikhin D; Schrier RW
    Curr Hypertens Rev; 2013 Feb; 9(1):12-20. PubMed ID: 23971639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
    Hilgers KF; Mann JF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3389-91. PubMed ID: 18687734
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal care of autosomal dominant polycystic kidney disease patients.
    Schrier RW
    Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.